Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infinity Gets More Than A Cash Boost With AbbVie Tie-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.

Advertisement

Related Content

Deal Watch: Merck Hopes Moderna's Personalized Vaccines Can Increase Keytruda Patient Base
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data
Infinity Gears Up For Duvelisib Filing, But Differentiation Still A Challenge
CLL Market Update: Imbruvica Leads Way, Jump-Started By Robust Launch
Start-Up Quarterly Statistics, Q3 2014
Deal Watch: Infinity Scores With AbbVie Deal, AbbVie Tries New Angle With Calico
Infinity Regains Pipeline Rights, Gives Up Equity In Rejiggered Purdue Alliance
Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS077726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel